NIH Reports Tecovirimat is Safe But Ineffective as Treatment for Clade II Mpox
NIH-sponsored trial data offers further evidence to help inform mpox treatment decisions. March 13, 2025 – The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain …